MGH Main Web 
Brain Tumor Center HomeBrain Tumor Center HomeBTC and Affiliates
- About Us
- Appointments
- BTC Textbook
- Consultations
- Education
- Fellowship in the BTC
- New Treatments
- News, etc.
- Research
- Services
- Spine Tumor Clinic
- Staff
- Support Groups
- Therapies
- Tumor Types
- BT Links
Search BTC Web
Brain Tumor Webs
- Brain Tumor Center
- Brain Tumor Research
- Neuro-Oncology
- Neurosurgery
- Neurology
- Radiation Oncology
Pappas Center @ MGH
Neuro-Oncology @ MGHNeurosurgery @ MGHNeurology @ MGHRadiation Oncology @ MGH


page home
The Power of Collaboration
Tracy Batchelor, MD, MPH

This double-whammy, shrinking both the tumor and the swelling, intrigued Batchelor. He, like Jain, wanted to find out if this normalization window also happens in humans. Jain knew cediranib had recently been approved for clinical trials. In 2005, Batchelor obtained funding from the National Cancer Institute to launch a clinical trial for 31 people with recurrent glioblastoma.

The team had a cancer biology expert, Jain, and a renowned oncologist, Batchelor. But it needed another ingredient, brain imaging, to track the changes in the tumor and swelling. “I knew that one of the top brain tumor imaging experts was right here at Massachusetts General,” says Batchelor. A. Gregory Sorensen, MD, associate professor of radiology and co-director of the Athinoula A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital, enthusiastically joined the study.

“Rakesh had questions about cediranib’s effect on cancer biology, and I could help answer some of those questions with imaging,” Sorensen explains. “Tracy could tell how the patients were faring. We had phenomenal imaging tools, but it was the unique integration of interpretations that mattered. Other groups could get the data but not have the mutual insights of science, imaging technology and medicine.”

Massachusetts General Hospital recognized the synergy, honoring the trio with its 2007 Clinical Research Team Award for their work on cediranib. Sorensen developed a protocol of six forms of MRIs to track aspects of the cancer biology and the mechanisms by which the drug worked. “Patients were eager to undergo imaging and learn what was happening to their tumors,” recalls Sorensen. Participants came from as far away as Tennessee and Florida every 28 days to lie in a scanner for an hour or more.

page home

Advancing the Specialized Care of Individuals with Brain Tumors
US News Home


MGH Brain Tumor Center
Yawkey Building 9th Floor
Boston, Massachusetts,  02114
Patients & Families with questions about referrals, consultations or appointments may contact:
Telephone: 617.724.8770
Fax: 617.724.8769


Physicians with
questions may contact:
Tracy Batchelor, M.D.
Executive Director,
MGH Brain Tumor Center
Harvard Medical School
Mass General Hospital
MGH Cancer Center
NS @ MGHNS Diagnosis @ MGH
Disclaimer About Medical Information: The information and reference materials contained herein is intended solely for the information of the reader. It should not be used for treatment purposes, but rather for discussion with the patient's own physician. All visitors to this and associated sites from the Neurosurgical Service at MGH agree to read and abide by the the complete terms of legal agreement found at the Neurosurgery "disclaimer & legal agreement." See also: the MGH Disclaimer, the MGH Privacy Policy, and the MGH Interactive Program Disclaimer - Copyright 2008 MGH Neurosurgical Service - All Rights Reserved. System Info Contact: C.Owen Neurosurgery@MGH IntraNet
Brain Tumor Center @ MGH MassGeneralWeb Partners Health Care Harvard Medical School